Robert M. Plenge's Insider Trades & SAST Disclosures
Robert M. Plenge's most recent trade in Bristol-Myers Squibb Co. was a trade of 35,146 Performance Shares done . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert M. Plenge.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 35,146 | 35,146 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 23,431 | 23,431 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,641 | 20,148 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 6,641 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 2,449 | 17,699 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,342 | 14,768 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,342 | 4,684 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 1,860 | 15,839 (0%) | 0% | 63.1 | 117,385 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,165 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,165 | 12,480 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,107 | 13,025 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,107 | 1,107 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 862 | 13,507 (0%) | 0% | 63.1 | 54,401 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 482 | 11,918 (0%) | 0% | 63.1 | 30,419 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 406 | 12,426 (0%) | 0% | 63.1 | 25,623 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 399 | 14,369 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 193 | 12,832 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 80 | 12,400 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 23,220 | 23,220 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 15,480 | 15,480 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,985 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,985 | 15,182 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 2,431 | 12,751 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 2,342 | 7,026 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 1,436 | 11,315 (0%) | 0% | 53.8 | 77,242 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 1,164 | 1,165 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 1,164 | 8,681 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 1,107 | 2,214 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 994 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 994 | 7,920 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 283 | 8,197 (0%) | 0% | 53.8 | 15,223 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 246 | 7,517 (0%) | 0% | 53.8 | 13,232 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 201 | 8,480 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb Co. | Robert M. Plenge | EVP, Chief Research Officer | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 157 | 7,763 (0%) | 0% | 0 | Common Stock, $0.10 par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges